Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




An Electrochemical Bio-barcode Device for Home Disease Monitoring and Diagnosis

By LabMedica International staff writers
Posted on 28 Oct 2020
A point-of-care (POC) electrochemical bio‐barcode device and assay system have been developed to enable analysis of protein biomarkers in undiluted and unprocessed human plasma samples.

There is a need for biosensing systems that can be operated at the POC for disease screening and diagnostics and health monitoring. More...
In spite of this, simple to operate systems with the required analytical sensitivity and specificity for clinical samples remain a rarity.

To correct this situation investigators at McMaster University (Hamilton, Canada) and Brock University (St. Catharines, Canada) devised an electrochemical bio‐barcode assay (e‐biobarcode assay) that integrated biorecognition with signal transduction using molecular (DNA/protein) machines and signal readout using nanostructured electrodes.

The design of the e‐biobarcode assay eliminated multistep processing and used a single step for analysis following sample collection into the reagent tube. In use, a drop of blood is added to a vial of reactive solution, and a small amount of the mixture is placed onto a strip and inserted into a reader. In minutes, the device determines the concentration of an antigen.

In the current study, the investigators demonstrated the clinically relevant determination of prostate specific antigen (PSA) - the biomarker for prostate cancer - in undiluted and unprocessed human plasma.

"This is another step toward truly personalized medicine," said senior author Dr. Leyla Soleymani, associate professor of engineering physics at McMaster University. "We are getting away from centralized, lab-based equipment for this kind of testing. This would make monitoring much more accessible and cut down on the number of times patients need to leave home to provide blood samples."

"Once commercialized, this device will be a paradigm shift for cancer diagnosis and prognosis," said contributing author Dr. Feng Li, associate professor of chemistry at Brock University. "Since this device is a lot more accessible and user-friendly than conventional technologies, patients will be more willing to use it, which can improve clinical outcomes and save lives."

The e‐biobarcode assay was described in the October 7, 2020, online edition of the journal Angewandte Chemie.

Related Links:
McMaster University
Brock University



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.